Pulse Biosciences Inc
pulsebiosciences.comWhat Do They Do?
Develops ablation systems for surgeons and heart specialists treating heart rhythm disorders, and sells a console and disposable electrodes for clinicians treating soft-tissue conditions.
10-K for FY2025, filed Feb 19, 2026We are a novel ablation company committed to health innovation using our patented Nano-pulse Stimulation (“NPS”) technology, a…View ↗
Our first product for soft tissue ablation in a surgical setting, the Vybrance Percutaneous Electrode System, consists of a disposable…View ↗
The results of preclinical and clinical testing of both our nPulse cardiac products, namely our surgical ablation clamp and our endocardial…View ↗
We believe our endocardial catheter ablation device will have many of the same advantages that the surgical ablation clamp appears to have…View ↗
The nPulse Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by…View ↗
How Do They Make Money?
Customers buy the nPulse Vybrance system, software, components and accessories, and generally pay shortly after the products are delivered.
$350K
-
10-K for FY2025, filed Feb 19, 2026
$350K ↗
Who Are Their Customers?
Clinical sites and commercial accounts use the system and electrodes in procedures; some U.S. sites work with Pulse Biosciences under short-term evaluation, consulting, or other early commercial agreements.
10-K for FY2025, filed Feb 19, 2026Since securing 510(k) clearance to market and sell the Vybrance Percutaneous Electrode System in the United States, we have engaged with…View ↗
More recently, in September 2025, we commenced a clinical trial (PRECISE BTN) to generate clinical evidence to demonstrate the safety and…View ↗
The Company accounts for a contract with a customer when the rights and obligations of the parties are identifiable, the contract has…View ↗
Do Revenues Turn Into Profits?
No. It lost $72.8M in FY2025.
10-K for FY2025, filed Feb 19, 2026
−$76.9MView ↗
10-K for FY2025, filed Feb 19, 2026
−$72.8MView ↗
10-K for FY2025, filed Feb 19, 2026
−$54.4MView ↗
How Are They Changing?
Shrinking. Revenue fell 75% in 4 years, from $1.4M in FY2021 to $350K in FY2025, about 30% a year.
Soft-tissue ablation
The older report limited development outside cardiology and atrial fibrillation, while the latest also pursues surgical soft-tissue ablation and a limited market release of its percutaneous electrodes.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Feb 19, 2026While we are not investing R&D resources in applications outside of cardiology and the treatment of AF, we continue to believe nsPFA…View ↗
Who Do They Compete With?
Competes with Abbott Laboratories, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic
10-K for FY2025, filed Feb 19, 2026Our medical products and products under development are for applications that are constantly under pressure from intense competition from…View ↗
Loading...
